Stock listing

Frankfurt:2H51 Ocugen, Inc. Aktie

German listing (Frankfurt) of Ocugen, Inc. · home listing NASDAQ:OCGN

Follow Ocugen, Inc. into a list and get an email when it puts out news.

Share price · FWB:2H51

€0.655 EUR -0.042 (-6.0%)

Close on Nov 20, 2026

Past year -13.7% · daily closes, Nov 20, 2025 – Nov 6, 2026, adjusted for splits
Day range
€0.655 – €0.655 EURNov 20, 2026
Volume
15,050 sharesNov 20, 2026
Market cap
€222.2M EURAt the close on Nov 20, 2026 · price × 339.3M shares outstanding
52-week range
€0.636 – €2.336 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
€15,493 EURMedian day 5,650 shares · 7 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026
Ocugen, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:OCGN · Home$0.768 USD+0.029 (+3.9%)6,186,721$0.710$0.820$0.710$0.739Close on Nov 20, 2026
Frankfurt:2H51€0.655 EUR-0.042 (-6.0%)15,050€0.655€0.655€0.655€0.697Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:2H51 · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€0.816+0.042+5.4%€0.721€0.820€0.7152,834
€0.774+0.011+1.4%€0.800€0.859€0.773332,696
€0.763+0.107+16.3%€0.676€0.769€0.66872,298
€0.656-0.006-0.9%€0.656€0.656€0.6564,350
€0.662+0.020+3.1%€0.656€0.676€0.65514,300
€0.642-0.053-7.6%€0.655€0.704€0.63914,300
€0.695-0.001-0.1%€0.684€0.703€0.6797,204
€0.696+0.013+1.9%€0.686€0.696€0.6856,000
€0.683+0.047+7.4%€0.652€0.697€0.64711,010
€0.636-0.057-8.2%€0.661€0.662€0.63611,000
€0.693-0.029-4.0%€0.702€0.707€0.6880
€0.722+0.023+3.3%€0.716€0.725€0.7121,000
€0.699-0.044-5.9%€0.739€0.745€0.69841,500
€0.743+0.019+2.6%€0.700€0.748€0.6981,000
€0.724+0.003+0.4%€0.708€0.735€0.7045,300
€0.721-0.021-2.8%€0.747€0.750€0.7180
€0.742-0.032-4.1%€0.765€0.770€0.73910,647
€0.774+0.005+0.7%€0.796€0.810€0.77263,800
€0.769-0.072-8.6%€0.839€0.845€0.76528,763
€0.841+0.018+2.2%€0.846€0.852€0.841147
€0.823-0.075-8.4%€0.872€0.874€0.82322,000
€0.898-0.044-4.7%€0.899€0.899€0.89110,000
€0.942+0.030+3.3%€0.928€0.947€0.91918,926
€0.912-0.017-1.8%€0.913€0.923€0.9091,000
€0.929+0.036+4.0%€0.913€0.930€0.90218,010
€0.893-0.018-2.0%€0.893€0.893€0.8931,760
€0.911+0.013+1.4%€0.911€0.911€0.911200
€0.898-0.008-0.9%€0.956€0.956€0.89526,500
€0.906+0.021+2.4%€0.901€0.908€0.8973,000
€0.885-0.031-3.4%€0.915€0.915€0.8825,500
€0.916+0.047+5.4%€0.871€0.945€0.86436,400
€0.869-0.011-1.3%€0.870€0.871€0.8691,423
€0.880-0.010-1.1%€0.916€0.917€0.87211,000
€0.890-0.032-3.5%€0.890€0.890€0.8900
€0.922+0.041+4.7%€0.922€0.922€0.9220
€0.881-0.009-1.0%€0.889€0.898€0.8718,605
€0.890+0.034+4.0%€0.875€0.892€0.8715,030
€0.856-0.008-0.9%€0.856€0.856€0.8560
€0.864-0.040-4.4%€0.900€0.922€0.8585,550
€0.904-0.002-0.2%€0.892€0.925€0.89013,400
€0.906+0.010+1.1%€0.858€0.910€0.85812,170
€0.896-0.042-4.5%€0.979€0.995€0.88914,350
€0.938-0.234-20.0%€1.126€1.137€0.92589,603
€1.172+0.018+1.6%€1.172€1.172€1.1720
€1.154+0.003+0.3%€1.157€1.157€1.15123,200
€1.151+0.012+1.1%€1.157€1.157€1.1492,000
€1.139-0.009-0.8%€1.150€1.178€1.13724,313
€1.148+0.012+1.1%€1.139€1.162€1.1333,950
€1.136+0.005+0.4%€1.143€1.143€1.1335
€1.131-0.037-3.2%€1.158€1.169€1.1245,650
€1.168-0.032-2.7%€1.167€1.169€1.1642,000
€1.200+0.025+2.1%€1.200€1.203€1.1942,600
€1.175-0.002-0.2%€1.176€1.176€1.1752,000
€1.1770.0000.0%€1.177€1.177€1.1770
€1.177-0.023-1.9%€1.201€1.204€1.1688,970
€1.200-0.081-6.3%€1.184€1.214€1.16338,032
€1.281+0.044+3.6%€1.259€1.290€1.241400

Splits

1 split · FWB:2H51 · every price before a split is adjusted for it

DayRatioWhat
1-for-60Consolidation
Ticker
Frankfurt:2H51
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Latest news

All Ocugen, Inc. news

Ocugen, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
39 in the last 12 months · 276 in all · newest Nov 10, 2026 · oldest 2019
Calls
23 calls with a replay · 23 with a transcript · latest Nov 4, 2026
Decks
75 decks · latest Nov 4, 2026

Where Ocugen, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:OCGN · Home listingNASDAQUnited StatesUSD
gettex:2H51gettexGermanyEUR
Tradegate:2H51TradegateGermanyEUR
LS Exchange:A2PSZHLS ExchangeGermanyEUR
BMV:OCGNBMVMexicoMXN
Lang & Schwarz:A2PSZHLang & SchwarzGermanyEUR
Frankfurt:2H51 · This pageFrankfurtGermanyEUR
Stuttgart:2H51StuttgartGermanyEUR
Munich:2H51MunichGermanyEUR
Dusseldorf:2H51DusseldorfGermanyEUR
BOATS:OCGNBOATSUnited StatesUSD
BIVA:OCGNBIVAMexicoMXN
Hamburg:2H51HamburgGermanyEUR
Hanover:2H51HanoverGermanyEUR
Xetra:2H51XetraGermanyEUR

Valuation

EV/sales 37.3× against a median of 6.3×: 3rd lowest of 4 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$178.1M USD
P/E
Loss
EV/sales
37.3×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
88.5%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
Negative equity
Beta vs S&P 500
1.47

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Ocugen, Inc. · NASDAQ:OCGNUS$260.6MUS$178.1Mn/a37.3×n/an/an/an/a1.47
Kyverna Therapeutics, Inc. · NASDAQ:KYTXUS$263.5MUS$117.8Mn/an/an/a2.0×n/a0.2×2.02
PepGen Inc. · NASDAQ:PEPGUS$261.8MUS$172.6Mn/an/an/a2.5×n/a0.1×1.11
Altimmune, Inc. · NASDAQ:ALTUS$258.8MUS$28.73Mn/an/an/a0.6×n/a0.1×1.55
Prelude Therapeutics Incorporated · NASDAQ:PRLDUS$258.6MUS$136.2Mn/a6.3×n/a2.1×−247.1%0.1×1.48
OBI Pharma, Inc. · TPEX:4174US$258.4MUS$243.3Mn/a154×n/a5.7×n/a0.0×n/a
TransThera Sciences (Nanjing). Inc. · HKEX:2617US$257.1MUS$119.1Mn/an/an/a1.9×n/a0.0×n/a
Eikon Therapeutics, Inc. · NASDAQ:EIKNUS$256.8MUS$44.67Mn/an/an/a0.7×n/a0.7×1.91
SAB Biotherapeutics, Inc. · NASDAQ:SABSUS$255.7MUS$156.5Mn/an/an/a1.2×n/a0.0×1.19
Evommune, Inc. · NYSE:EVMNUS$255.5MUS$86.86Mn/an/an/a1.0×n/a0.0×0.96
Editas Medicine, Inc. · NASDAQ:EDITUS$253.1MUS$119.7Mn/a2.4×n/a3.0×−144.9%0.7×2.22
Median of the othersUS$257.8MUS$119.4M6.3×2.0×−196.0%0.1×1.52

Forecasts

5 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.

Price target
12.17 USD · Analysts' mean
EPS, year to Dec 2026
-0.20 · 6 analysts
Revenue, year to Dec 2026
5.99M · 6 analysts

Team and board

Officers

OfficerRole
Shankar MusunuriChairman of the Board, CEO and Co-founder
Rita Johnson-GreeneChief Financial Officer
Abhi GuptaExecutive Vice President, Commercial and Business Development
Chris ClarkVP Communications
Paul StaidExecutive Vice President, Operations
Tiffany HamiltonAVP, Head of Communications
Arun UpadhyayChief Scientific Officer, Head of Research & Development
Mohamed GeneadChief Medical Officer
Uday B. KompellaCo-founder and Director
Vijay TammaraChief Development Officer

Board

DirectorRole
Shankar MusunuriChairman of the Board, CEO and Co-founder
Blaise ColemanDirector
John ZhangDirector
Junge ZhangDirector
Kirsten CastilloDirector
Satish ChandranDirector
Uday B. KompellaCo-founder and Director

Events

Calls

CallWhenStatus
Ocugen (NASDAQ:OCGN) Q3 2026 Earnings CallWed, Nov 04, 2026 · 8:30 AM ETReplay
Ocugen (NASDAQ:OCGN) Q2 2026 Earnings CallThu, Aug 06, 2026 · 8:30 AM ETReplay
Ocugen (NASDAQ:OCGN) Q1 2026 Earnings CallTue, May 05, 2026 · 8:30 AM ETReplay
Ocugen (NASDAQ:OCGN) Q4 2025 Earnings CallWed, Mar 04, 2026 · 8:30 AM ETReplay
Ocugen (NASDAQ:OCGN) Q3 2025 Earnings CallWed, Nov 05, 2025 · 8:30 AM ETReplay
Ocugen (NASDAQ:OCGN) Q2 2025 Earnings CallFri, Aug 01, 2025 · 8:30 AM ETReplay
Ocugen (NASDAQ:OCGN) Q1 2025 Earnings CallFri, May 09, 2025 · 8:30 AM ETReplay
Ocugen (NASDAQ:OCGN) Q4 2024 Earnings CallWed, Mar 05, 2025 · 8:30 AM ETReplay
Ocugen (NASDAQ:OCGN) Q3 2024 Earnings CallFri, Nov 08, 2024 · 8:30 AM ETReplay
Ocugen (NASDAQ:OCGN) Q2 2024 Earnings CallThu, Aug 08, 2024 · 8:30 AM ETReplay
All 23 calls
CallWhenStatus
Ocugen (NASDAQ:OCGN) Q1 2024 Earnings CallTue, May 14, 2024 · 8:30 AM ETReplay
Ocugen (NASDAQ:OCGN) Q3 2023 Earnings CallThu, Nov 09, 2023 · 8:30 AM ETReplay
Ocugen (NASDAQ:OCGN) Q2 2023 Earnings CallTue, Aug 22, 2023 · 8:30 AM ETReplay
Ocugen (NASDAQ:OCGN) Q1 2023 Earnings CallFri, May 05, 2023 · 8:30 AM ETReplay
Ocugen (NASDAQ:OCGN) Q4 2022 Earnings CallTue, Feb 28, 2023 · 8:30 AM ETReplay
Ocugen (NASDAQ:OCGN) Q3 2022 Earnings CallTue, Nov 08, 2022 · 8:30 AM ETReplay
Ocugen (NASDAQ:OCGN) Q2 2022 Earnings CallFri, Aug 05, 2022 · 8:30 AM ETReplay
Ocugen (NASDAQ:OCGN) Q1 2022 Earnings CallFri, May 06, 2022 · 8:30 AM ETReplay
Ocugen (NASDAQ:OCGN) Q4 2021 Earnings CallFri, Feb 25, 2022 · 8:30 AM ETReplay
Ocugen (NASDAQ:OCGN) Q3 2021 Earnings CallTue, Nov 09, 2021 · 8:30 AM ETReplay
Ocugen (NASDAQ:OCGN) Q2 2021 Earnings CallFri, Aug 06, 2021 · 8:30 AM ETReplay
Ocugen (NASDAQ:OCGN) Q1 2021 Earnings CallFri, May 07, 2021 · 8:30 AM ETReplay
Ocugen (NASDAQ:OCGN) Q4 2020 Earnings CallThu, Mar 18, 2021 · 8:30 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 4, 2026 · Before open+17.4%
Q2 2026Aug 6, 2026 · Before open−3.1%
Q1 2026May 5, 2026 · After close−2.4%
Q4 2025Mar 27, 2026−10.7%
Q3 2025Nov 5, 2025 · Before open−1.4%
Q2 2025Aug 1, 2025 · After close+0.6%
Q1 2025May 9, 2025 · Before open−2.8%
Q4 2024Mar 31, 2025 · Before open−11.7%
Q3 2024Nov 14, 2024 · After close−6.1%
Q2 2024Aug 8, 2024 · Before open+8.5%
All 20 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · Before open−6.1%
Q4 2023Feb 7, 2024 · Before open+1.5%
Q3 2023Nov 9, 2023 · Before open−4.1%
Q2 2023Aug 21, 2023 · After close−9.0%
Q1 2023May 5, 2023 · Before open+0.7%
Q4 2022Feb 28, 2023 · Before open+2.1%
Q3 2022Nov 8, 2022 · Before open+7.2%
Q2 2022Aug 5, 2022 · Before open+3.3%
Q1 2022May 6, 2022 · Before open−5.3%
Q4 2021Feb 25, 2022 · Before open+5.4%

Open Events

Decks

DeckKindSlidesDate
Q3 2026 Earnings PresentationEarnings16 slidesNov 4, 2026
Investor Presentation (October 2026)Investor deck32 slidesOct 15, 2026
Investor Presentation (September 2026)Investor deck28 slidesSep 8, 2026
Q2 2026 Earnings PresentationEarnings11 slidesAug 6, 2026
Q1 2026 Earnings PresentationEarnings20 slidesMay 5, 2026
Investor Presentation (March 2026)Investor deck33 slidesMar 27, 2026
Investor Presentation (March 2026)Investor deck35 slidesMar 24, 2026
Technical Presentation (March 2026)Technical14 slidesMar 24, 2026
Q4 2025 Earnings PresentationEarnings25 slidesMar 4, 2026
Investor Presentation (January 2026)Investor deck37 slidesJan 15, 2026
Show 50 decks
DeckKindSlidesDate
Q3 2025 Earnings PresentationEarnings15 slidesNov 5, 2025
Q2 2025 Earnings PresentationEarnings18 slidesAug 1, 2025
BIO 2025Conference20 slidesJun 17, 2025
Q1 2025 Earnings PresentationEarnings21 slidesMay 9, 2025
Eyecelerator May 2025Conference17 slidesMay 1, 2025
Conference Presentation (April 2025)Conference21 slidesApr 4, 2025
FY2024 Earnings PresentationEarnings22 slidesMar 5, 2025
Investor Presentation (March 2025)Investor deck32 slidesMar 3, 2025
Investor Presentation (February 2025)Investor deck28 slidesFeb 12, 2025
Investor Presentation (January 2025)Investor deck27 slidesJan 29, 2025
Investor Presentation (December 2024)Investor deck25 slidesDec 3, 2024
Investor Day (November 2024)Investor day49 slidesNov 12, 2024
Q3 2024 Earnings PresentationEarnings14 slidesNov 8, 2024
Investor Presentation (August 2024)Investor deck21 slidesAug 13, 2024
Q2 2024 Earnings PresentationEarnings15 slidesAug 8, 2024
Q1 2024 Earnings PresentationEarnings16 slidesMay 14, 2024
FY2023 Earnings PresentationEarnings11 slidesApr 2, 2024
Investor Day (February 2024)Investor day27 slidesFeb 21, 2024
Investor Presentation (November 2023)Investor deck23 slidesNov 9, 2023
Q3 2023 Earnings PresentationEarnings19 slidesNov 9, 2023
Technical Presentation (September 2023)Technical16 slidesSep 13, 2023
Q2 2023 Earnings PresentationEarnings14 slidesAug 22, 2023
BIO International 2023Conference14 slidesJun 5, 2023
Investor Presentation (May 2023)Investor deck23 slidesMay 5, 2023
Q1 2023 Earnings PresentationEarnings18 slidesMay 5, 2023
Corporate Update (April 2023)Corporate update12 slidesApr 14, 2023
Investor Presentation (March 2023)Investor deck25 slidesMar 13, 2023
FY2022 Earnings PresentationEarnings13 slidesFeb 28, 2023
Investor Presentation (February 2023)Investor deck25 slidesFeb 6, 2023
Investor Presentation (January 2023)Investor deck26 slidesJan 9, 2023
Investor Presentation (November 2022)Investor deck25 slidesNov 8, 2022
Q3 2022 Earnings PresentationEarnings14 slidesNov 8, 2022
Technical Presentation (November 2022)Technical35 slidesNov 1, 2022
Investor Day (November 2022)Investor day9 slidesNov 1, 2022
Investor Presentation (August 2022)Investor deck23 slidesAug 26, 2022
Investor Presentation (August 2022)Investor deck21 slidesAug 17, 2022
Investor Presentation (August 2022)Investor deck25 slidesAug 16, 2022
Q2 2022 Earnings PresentationEarnings10 slidesAug 5, 2022
Investor Presentation (May 2022)Investor deck17 slidesMay 6, 2022
Q1 2022 Earnings PresentationEarnings9 slidesMay 6, 2022

This page holds 50 of 75 decks. Open Decks

Open Decks

Financings

RaiseDate
6.75% convertible senior notes due 2034
Update: US$115M–US$130M
Use of proceeds: $32.7 million to retire the Avenue debt; remaining net proceeds for general corporate purposes
May 5, 2026
Public offering of common stock
Announced: US$22.5M · US$1.5 a share · Oppenheimer & Co.
Dealers: Oppenheimer & Co. (lead)
Buyers: RTW Investments
Use of proceeds: General corporate purposes, capital expenditures, working capital, and general and administrative expenses
Jan 21, 2026
Registered direct offering of common stock and warrants
Closed: US$20M raised · US$1 a share · Warrants at US$1.5 for 24 months · Noble Capital Markets, Inc. +2
Dealers: Noble Capital Markets, Inc. (lead), Maxim Group LLC, Titan Partners Group
Buyers: Janus Henderson Investors (20,000,000 shares of common stock and warrants to purchase up to 20,000,000 shares)
Use of proceeds: Extend the company's cash runway into the second quarter of 2026
Aug 12, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as HISTOGENICS CORP. Priced at US$11.00 a share on Dec 2, 2014.

Price
US$11.00 a share
Shares offered
5,909,091 shares of common stock
Offering size
US$65 million
Underwriters
Cowen and Company, Needham & Company, Canaccord Genuity, BTIG · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceFeb 14, 2014
Filed publiclyOct 7, 2014
Amended 4 timesNewest Dec 2, 2014
Shares registered with an exchangeNov 18, 2014
Declared effective by the SECDec 2, 2014
Final prospectus, with the priceDec 3, 2014

Open IPO · From the cover of the final prospectus (424B4) filed Dec 3, 2014

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue4.41M4.05M6.04M2.49M043.0K0000
Cost of revenue2.39M1.97M704.0K1.07M589.0K6.35M8.09M49.6K1.53M1.67M
Gross profit2.02M2.09M5.33M-1.07M-589.0K-6.31M-8.09M-49.6K-1.53M-1.67M
Research and development39.8M32.1M39.6M56.2M35.1M6.35M8.09M10.3M15.6M21.6M
Selling, general and administrative27.6M26.7M32.0M35.1M22.9M7.97M6.08M10.2M9.38M8.53M
Operating income-62.9M-54.8M-65.5M-89.1M-58.0M-21.3M-14.2M-16.1M-24.9M-30.3M
Depreciation and amortization2.40M1.90M700.0K480.0K229.0K100.0K100.0K49.6K1.53M1.67M
EBITDA-60.5M-52.9M-64.8M-88.6M-57.8M-21.2M-14.1M-16.1M-23.4M-28.6M
Interest expense5.19M688.0K3.52M79.0K721.0K1.77M3.75M134.0K60.0K
Income before tax-67.8M-54.1M-63.1M-86.8M-58.4M-21.8M-20.2M-8.64M-26.4M-16.2M
Income tax0000-52.0K00-15.8M-186.0K-15.8M
Net income-67.8M-54.1M-63.1M-86.8M-58.4M-21.8M-20.2M-18.2M-26.4M-16.2M
Earnings per share, basic-0.22-0.19-0.26-0.40-0.30-0.31-1.46-0.23-0.99-0.97
Earnings per share, diluted-0.26-0.40-0.30-0.31-1.46-0.79-0.99-2.18

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents18.6M58.5M39.5M77.6M95.0M24.0M7.44M1.63M7.08M31.9M
Short-term investments0013.4M00900.0K
Receivables4.99M
Inventory4.99M
Current assets24.3M61.7M43.0M98.5M102.6M25.9M15.8M1.94M8.18M32.1M
Property, plant and equipment14.4M16.6M17.3M6.05M1.16M633.0K222.5K245.8K2.72M3.86M
Total assets43.5M82.4M64.5M108.6M105.8M27.4M16.8M2.45M11.0M36.1M
Accounts payable6.20M4.24M3.17M8.06M2.31M395.0K1.90M3.28M776.0K1.59M
Current liabilities23.0M21.6M17.1M28.5M7.00M3.61M4.54M14.1M3.81M5.17M
Long-term debt27.5M27.3M2.80M2.29M1.71M1.82M1.07M1.02M961.7K178.0K
Total debt28.8M28.7M2.80M2.29M1.71M2.29M1.07M8.50M178.0K761.0K
Total liabilities55.7M52.8M24.0M34.7M9.94M5.83M5.79M15.2M22.3M22.5M
Shareholders' equity-12.2M29.6M40.6M74.0M91.2M21.6M11.0M-12.7M4.43M13.6M
Shares outstanding312.4M291.4M256.6M221.6M199.4M184.0M52.6M4.96M24.6M20.6M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-57.0M-42.1M-62.1M-60.1M-47.9M-14.7M-16.9M-11.6M-23.0M-25.7M
Capital spending-185.0K-3.38M-10.5M-4.46M-939.0K-307.0K-30.0K-77.4K-276.0K-320.0K
Free cash flow-57.1M-45.5M-72.5M-64.5M-48.9M-15.0M-16.9M-11.7M-23.3M-26.1M
Cash from investing-311.0K-3.38M3.08M-17.0M-1.82M-307.0K-2.36M-77.4K-1.23M-320.0K
Cash from financing17.3M64.9M20.9M59.5M120.7M31.6M25.1M7.18M-577.0K27.0M
Dividends paid-6.80M
Share buybacks00-48.0K06.00K27.6M
Change in cash-39.9M19.4M-38.1M-17.5M70.9M16.6M5.82M-4.52M-24.8M993.0K

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 10, 2026Material contractSEC
DEFA14A · Additional proxy materialNov 6, 2026Meeting noticeSEC
DEFA14A · Additional proxy materialNov 6, 2026Meeting noticeSEC
10-Q · Quarterly reportNov 4, 2026Quarterly reportSEC
8-K · Current reportNov 4, 2026ResultsSEC
8-K · Current reportOct 15, 2026Current reportSEC
8-K · Current reportOct 14, 2026Material contractSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
144 · Notice of proposed saleOct 9, 2026Other filingsSEC
8-K · Current reportOct 5, 2026Meeting outcomeSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportSep 22, 2026Meeting outcomeSEC
4 · Change in ownershipSep 11, 2026Insider tradeSEC
144 · Notice of proposed saleSep 9, 2026Other filingsSEC
8-K · Current reportSep 8, 2026Current reportSEC
DEFA14A · Additional proxy materialAug 13, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 7, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
DEFA14A · Additional proxy materialJul 30, 2026Meeting noticeSEC
DEF 14A · Proxy statementJul 30, 2026Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeJul 29, 2026Big-stake noticeSEC
PRE 14A · Preliminary proxy statementJul 20, 2026Meeting noticeSEC
8-K · Current reportJul 13, 2026Current reportSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
8-K · Current reportJun 11, 2026Meeting outcomeSEC
8-K · Current reportJun 3, 2026Management or board changeSEC
8-K · Current reportMay 14, 2026Management or board changeSEC
8-K · Current reportMay 14, 2026FinancingSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
8-K · Current reportMay 5, 2026ResultsSEC
8-K · Current reportMay 4, 2026ResultsSEC
DEFA14A · Additional proxy materialApr 28, 2026Meeting noticeSEC
ARS · Annual report to shareholdersApr 28, 2026Annual reportSEC
DEF 14A · Proxy statementApr 28, 2026Meeting noticeSEC
PRER14AApr 20, 2026Other filingsSEC
PRE 14A · Preliminary proxy statementApr 17, 2026Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeApr 14, 2026Big-stake noticeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 27, 2026Big-stake noticeSEC
8-K · Current reportMar 26, 2026Current reportSEC
8-K · Current reportMar 24, 2026Current reportSEC
8-K · Current reportMar 20, 2026Current reportSEC
3 · Initial statement of ownershipMar 5, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMar 4, 2026Offer documentSEC
10-K · Annual reportMar 4, 2026Annual reportSEC
8-K · Current reportMar 4, 2026Current reportSEC
8-K · Current reportMar 4, 2026ResultsSEC
8-K · Current reportFeb 9, 2026Management or board changeSEC
SCHEDULE 13G · Big-stake noticeJan 30, 2026Big-stake noticeSEC
8-K · Current reportJan 23, 2026Current reportSEC
8-K · Current reportJan 21, 2026Material contractSEC
424B5 · ProspectusJan 21, 2026Offer documentSEC
8-K · Current reportJan 15, 2026Current reportSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
8-K · Current reportDec 18, 2025Management or board changeSEC
SCHEDULE 13G · Big-stake noticeDec 8, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2025Quarterly reportSEC
8-K · Current reportNov 5, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 31, 2025Big-stake noticeSEC
8-K · Current reportSep 18, 2025Current reportSEC
8-K · Current reportSep 15, 2025Material contractSEC
8-K · Current reportSep 5, 2025Material contractSEC
8-K · Current reportAug 11, 2025Material contractSEC
424B5 · ProspectusAug 11, 2025Offer documentSEC
10-Q · Quarterly reportAug 4, 2025Quarterly reportSEC
8-K · Current reportAug 1, 2025ResultsSEC
8-K · Current reportJul 30, 2025Current reportSEC
8-K · Current reportJul 29, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 17, 2025Big-stake noticeSEC
144 · Notice of proposed saleJul 9, 2025Other filingsSEC
8-K · Current reportJul 1, 2025Current reportSEC
8-K · Current reportJun 23, 2025Material contractSEC
8-K · Current reportJun 16, 2025Current reportSEC
3/A · Initial statement of ownership, amendedJun 12, 2025Insider tradeSEC
144 · Notice of proposed saleJun 11, 2025Other filingsSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 9, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 9, 2025Insider tradeSEC
8-K · Current reportJun 5, 2025Meeting outcomeSEC
8-K · Current reportMay 9, 2025ResultsSEC
10-Q · Quarterly reportMay 9, 2025Quarterly reportSEC
8-K · Current reportMay 1, 2025Current reportSEC
ARS · Annual report to shareholdersApr 25, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 25, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2025Meeting noticeSEC
8-K · Current reportApr 25, 2025Management or board changeSEC
8-K · Current reportApr 4, 2025Current reportSEC
S-8 · Registration statement for employee plansMar 5, 2025Offer documentSEC
10-K · Annual reportMar 5, 2025Annual reportSEC
8-K · Current reportMar 5, 2025ResultsSEC
8-K · Current reportMar 3, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveFeb 14, 2025Other filingsSEC
8-K · Current reportFeb 12, 2025Current reportSEC
CORRESP · Letter to the SECFeb 11, 2025Other filingsSEC
8-K/A · Current report, amendedFeb 7, 2025Material contractSEC
UPLOAD · Letter from the SECFeb 6, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeFeb 5, 2025Big-stake noticeSEC
S-3 · Registration statementJan 31, 2025Offer documentSEC
8-K · Current reportJan 29, 2025Current reportSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
8-K · Current reportJan 3, 2025Current reportSEC
8-K · Current reportDec 3, 2024Current reportSEC
4 · Change in ownershipDec 2, 2024Insider tradeSEC
4 · Change in ownershipNov 26, 2024Insider tradeSEC
3 · Initial statement of ownershipNov 15, 2024Insider tradeSEC
8-K · Current reportNov 15, 2024Management or board changeSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
8-K · Current reportNov 12, 2024Current reportSEC
8-K · Current reportNov 8, 2024Material contractSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
8-K · Current reportNov 8, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 4, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 22, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 16, 2024Big-stake noticeSEC
4 · Change in ownershipSep 26, 2024Insider tradeSEC
144 · Notice of proposed saleAug 16, 2024Other filingsSEC
8-K · Current reportAug 13, 2024Current reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 5, 2024Current reportSEC
424B5 · ProspectusAug 1, 2024Offer documentSEC
8-K · Current reportAug 1, 2024Material contractSEC
424B5 · ProspectusJul 31, 2024Offer documentSEC
8-K · Current reportJul 8, 2024Current reportSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC
8-K · Current reportJun 28, 2024Meeting outcomeSEC
DEFA14A · Additional proxy materialJun 18, 2024Meeting noticeSEC
8-K · Current reportJun 6, 2024Current reportSEC
ARS · Annual report to shareholdersMay 28, 2024Annual reportSEC
DEF 14A · Proxy statementMay 28, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementMay 17, 2024Meeting noticeSEC
8-K · Current reportMay 14, 2024ResultsSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
8-A12G · Registration of a class of sharesMay 10, 2024Other filingsSEC
8-K · Current reportMay 10, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveMay 2, 2024Other filingsSEC
CORRESP · Letter to the SECApr 29, 2024Other filingsSEC
10-K/A · Annual report, amendedApr 29, 2024Annual reportSEC
8-K · Current reportApr 29, 2024Current reportSEC
UPLOAD · Letter from the SECApr 25, 2024Other filingsSEC
S-3 · Registration statementApr 17, 2024Offer documentSEC
S-8 · Registration statement for employee plansApr 17, 2024Offer documentSEC
4 · Change in ownershipApr 17, 2024Insider tradeSEC
10-K · Annual reportApr 16, 2024Annual reportSEC
8-K · Current reportApr 8, 2024Current reportSEC
8-K · Current reportApr 2, 2024ResultsSEC
8-K · Current reportApr 1, 2024Current reportSEC
NT 10-K · Late filing noticeApr 1, 2024Explanation requestSEC
8-K · Current reportMar 21, 2024Current reportSEC
3 · Initial statement of ownershipMar 20, 2024Insider tradeSEC
3 · Initial statement of ownershipMar 20, 2024Insider tradeSEC
8-K · Current reportMar 20, 2024Management or board changeSEC
8-K · Current reportMar 18, 2024Current reportSEC
8-K · Current reportFeb 21, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 22, 2024Big-stake noticeSEC
8-K · Current reportJan 8, 2024Management or board changeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
4 · Change in ownershipJan 5, 2024Insider tradeSEC
4 · Change in ownershipJan 4, 2024Insider tradeSEC
4 · Change in ownershipJan 4, 2024Insider tradeSEC
8-K · Current reportDec 22, 2023Current reportSEC
8-K · Current reportNov 9, 2023Current reportSEC
8-K · Current reportNov 9, 2023ResultsSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
8-K · Current reportNov 1, 2023Current reportSEC
UPLOAD · Letter from the SECOct 12, 2023Other filingsSEC
8-K · Current reportOct 10, 2023Current reportSEC
CORRESP · Letter to the SECOct 4, 2023Other filingsSEC
8-K · Current reportSep 19, 2023Management or board changeSEC
4 · Change in ownershipSep 19, 2023Insider tradeSEC
UPLOAD · Letter from the SECSep 19, 2023Other filingsSEC
8-K · Current reportSep 13, 2023Current reportSEC
8-K · Current reportAug 22, 2023ResultsSEC
8-K · Current reportAug 21, 2023ResultsSEC
10-Q · Quarterly reportAug 21, 2023Quarterly reportSEC
NT 10-Q · Late filing noticeAug 15, 2023Explanation requestSEC
8-K · Current reportAug 15, 2023Management or board changeSEC
SC 13G/A · Big-stake notice, amendedJul 7, 2023Big-stake noticeSEC

This page holds 200 of 895 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Ocugen, Inc.’s releases · as of Oct 30, 2026

Common shares
339,306,603
Fully diluted
339,306,603

Fully diluted

LineSharesAs of
Common shares339,306,603Oct 30, 2026

Warrants and options

Lot
Warrants · US$1.50 · expire about Aug 2027

Share count over time

CountShares
Oct 30, 2026339,306,603

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
BlackRock27.8M8.2%US$28.6MSep 30, 2026
Vanguard20M5.9%US$20.7MSep 30, 2026
State Street19.5M5.8%US$20.1MSep 30, 2026
Millennium12.2M3.6%US$12.5MSep 30, 2026
UBS9.56M2.8%US$9.84MSep 30, 2026
Geode Capital8.66M2.6%US$8.92MSep 30, 2026
Rtw Investments, LP6.67M2.0%US$6.87MSep 30, 2026
Two Sigma3.94M1.2%US$4.06MSep 30, 2026
Ikarian Capital, LLC3.56M1.1%US$3.67MSep 30, 2026
GMT Capital Corp3.51M1.0%US$3.61MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Hennion & Walsh Asset Management, Inc.3.39M1.00%US$3.49MSep 30, 2026
Goldman Sachs3.32M0.98%US$3.42MSep 30, 2026
Northern Trust2.74M0.81%US$2.82MSep 30, 2026
Marshall Wace, LLP1.67M0.49%US$1.72MSep 30, 2026
Bank of America1.46M0.43%US$1.5MSep 30, 2026
Susquehanna1.25M0.37%US$1.28MSep 30, 2026
Wellington1.23M0.36%US$1.27MSep 30, 2026
BNP Paribas1.15M0.34%US$1.19MSep 30, 2026
Schwab1.04M0.31%US$1.07MSep 30, 2026
Boothbay Fund Management, LLC987K0.29%US$1.02MSep 30, 2026
Nuveen861K0.25%US$887KSep 30, 2026
BNY809K0.24%US$833KSep 30, 2026
Voleon Capital Management LP735K0.22%US$757KSep 30, 2026
Morgan Stanley608K0.18%US$627KSep 30, 2026
Quadrature Capital Ltd598K0.18%US$615KSep 30, 2026
Point72 Asset Management, L.P.526K0.15%US$542KSep 30, 2026
Rafferty Asset Management, LLC470K0.14%US$484KSep 30, 2026
Procyon Advisors, LLC461K0.14%US$475KSep 30, 2026
Barclays427K0.13%US$440KSep 30, 2026
Rhumbline Advisers348K0.10%US$359KSep 30, 2026
Osaic Holdings, Inc.308K0.09%US$335KSep 30, 2026
DWS296K0.09%US$305KSep 30, 2026
T. Rowe Price281K0.08%US$290KSep 30, 2026
Citigroup Inc255K0.08%US$263KSep 30, 2026
Silverback Asset Management LLC250K0.07%US$258KSep 30, 2026
NewEdge Advisors, LLC249K0.07%US$257KSep 30, 2026
Creative Planning232K0.07%US$239KSep 30, 2026
JPMorgan228K0.07%US$248KSep 30, 2026
XTX Topco Ltd217K0.06%US$224KSep 30, 2026
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.204K0.06%US$212KSep 30, 2026
Diadema Partners LP200K0.06%US$206KSep 30, 2026
AllianceBernstein179K0.05%US$184KSep 30, 2026
Invesco174K0.05%US$179KSep 30, 2026
MUFG171K0.05%US$176KSep 30, 2026
Pinnacle Financial Group, Inc.170K0.05%US$175KSep 30, 2026
Profund Advisors LLC166K0.05%US$171KSep 30, 2026
MetLife Investment Management, LLC161K0.05%US$166KSep 30, 2026
Prosperity Wealth Management, Inc.155K0.05%US$160KSep 30, 2026
Fidelity154K0.05%US$159KSep 30, 2026
Cora Capital Advisors LLC118K0.03%US$121KSep 30, 2026

This page holds 50 of 142 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF14M4.1%US$21.4MJun 30, 2026
Vanguard Total Stock Market Index Fund10.2M3.0%US$15.6MJun 30, 2026
iShares Russell 2000 ETF8.72M2.6%US$13.3MJun 30, 2026
Vanguard Extended Market Index Fund3.88M1.1%US$5.94MJun 30, 2026
Fidelity Small Cap Index Fund3.71M1.1%US$4.56MJul 31, 2026
iShares Russell 2000 Growth ETF2.21M0.65%US$3.38MJun 30, 2026
State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF1.82M0.54%US$2.78MJun 30, 2026
Fidelity Extended Market Index Fund1.7M0.50%US$2.35MMay 31, 2026
iShares Micro-Cap ETF1.15M0.34%US$1.76MJun 30, 2026
iShares Russell 2000 Value ETF997K0.29%US$1.52MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Vanguard Health Care Index Fund932K0.27%US$1.29MMay 31, 2026
Schwab Small-Cap Index Fund831K0.24%US$1.02MJul 31, 2026
iShares Genomics Immunology and Healthcare ETF724K0.21%US$890KJul 31, 2026
iShares Core S&P Total U.S. Stock Market ETF662K0.19%US$1.01MJun 30, 2026
Master Small Cap Index Series639K0.19%US$977KJun 30, 2026
Fidelity Total Market Index Fund604K0.18%US$833KMay 31, 2026
Fidelity Series Total Market Index Fund501K0.15%US$692KMay 31, 2026
Direxion Daily S&P Biotech Bull 3X Shares475K0.14%US$585KJul 31, 2026
Nuveen Small Cap Blend Index Fund454K0.13%US$558KJul 31, 2026
EQ/2000 Managed Volatility Portfolio369K0.11%US$565KJun 30, 2026
Nuveen Equity Index Fund282K0.08%US$347KJul 31, 2026
LVIP State Street Small-Cap Index Fund247K0.07%US$378KJun 30, 2026
Fidelity Small Cap Growth Index Fund221K0.06%US$337KJun 30, 2026
Schwab Total Stock Market Index Fund210K0.06%US$259KJul 31, 2026
Fidelity Nasdaq Composite Index Fund194K0.06%US$268KMay 31, 2026
Small Cap Index Fund177K0.05%US$270KJun 30, 2026
Fidelity ZERO Total Market Index Fund175K0.05%US$216KJul 31, 2026
Vanguard Balanced Index Fund167K0.05%US$255KJun 30, 2026
Global X Russell 2000 ETF163K0.05%US$200KJul 31, 2026
Vanguard Institutional Total Stock Market Index Fund147K0.04%US$225KJun 30, 2026
Fidelity Small Cap Value Index Fund147K0.04%US$225KJun 30, 2026
Biotechnology Ultrasector Profund133K0.04%US$164KJul 31, 2026
Fidelity Nasdaq Composite Index ETF132K0.04%US$182KMay 31, 2026
Fidelity ZERO Extended Market Index Fund125K0.04%US$153KJul 31, 2026
ATM Small Cap Managed Volatility Portfolio117K0.03%US$179KJun 30, 2026
MetLife Russell 2000 Index Portfolio114K0.03%US$175KJun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio109K0.03%US$167KJun 30, 2026
Small-Cap Index Portfolio97,3530.03%US$149KJun 30, 2026
1290 VT Micro Cap Portfolio76,5860.02%US$117KJun 30, 2026
NVIT Small Cap Index Fund75,1930.02%US$115KJun 30, 2026
Small Cap Index Trust71,4740.02%US$109KJun 30, 2026
Goldman Sachs Absolute Return Tracker Fund70,0020.02%US$107KJun 30, 2026
EQ/AB Small Cap Growth Portfolio68,7400.02%US$105KJun 30, 2026
EQ/Small Company Index Portfolio68,7400.02%US$105KJun 30, 2026
Goldman Sachs Innovate Equity ETF63,3630.02%US$87,441May 31, 2026
Profund Vp Biotechnology62,0110.02%US$94,877Jun 30, 2026
iShares Russell Small/Mid-Cap Index Fund60,4030.02%US$74,296Jul 31, 2026
DWS Small Cap Index VIP53,6010.02%US$82,010Jun 30, 2026
Fidelity Flex Small Cap Index Fund52,4490.02%US$64,512Jul 31, 2026
T. Rowe Price Small-Cap Index Fund51,5310.02%US$78,842Jun 30, 2026

This page holds 50 of 86 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Musunuri Shankar
Director, Officer: Chief Executive Officer
Sale468,727USD 0.95US$445KOct 9, 2026
Musunuri Shankar
Director, Officer: Chief Executive Officer
Sale57,264USD 0.95US$54,401Oct 9, 2026
Musunuri Shankar
Director, Officer: Chief Executive Officer
Sale468,727USD 1.12US$525KSep 9, 2026
Musunuri Shankar
Director, Officer: Chief Executive Officer
Sale57,264USD 1.12US$64,136Sep 9, 2026
Johnson-Greene Treerita Essalima
Officer: Chief Financial Officer
Buy21,000USD 1.23US$25,830Jun 15, 2026

Big stakes

StakeStakeSharesDateFiling
BlackRock, Inc.8.00%27MJun 30, 2026Schedule 13G
State Street Corp6.30%21.5MJun 30, 2026Schedule 13G
Millennium Management LLC5.20%17.1MApr 9, 2026Schedule 13G
Janus Henderson Group PLC3.00%10MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
John H. Johnson
Other companies: Xeris Biopharma Holdings, Inc. (Independent, Non-executive Board Member · Since at least Oct 5, 2021); Axogen, Inc. (Director · Since at least Jul 19, 2021); Verastem, Inc. (Director · Since at least Apr 23, 2020); Applied Therapeutics Inc (Executive Chairman, Director · Dec 19, 2024 – Dec 19, 2024 · Past); Melinta Therapeutics Inc (Chief Executive Officer, Director · Jun 12, 2018 – Jun 27, 2019 · Past); AVEO Pharmaceuticals Inc (Director · Feb 1, 2018 – Feb 1, 2018 · Past); Strongbridge Biopharma plc (Chief Executive Officer, Director · Jan 1, 2018 – Oct 5, 2021 · Past); Cempra Inc (Director · Jan 3, 2017 – Jan 3, 2017 · Past); Portola Pharmaceuticals Inc (Director · Jun 17, 2016 – Jul 2, 2020 · Past); Sucampo Pharmaceuticals Inc (Director · Jun 2, 2016 – Feb 13, 2018 · Past)
Director · Dec 16, 2016 – Jun 15, 2018 · Past
David Gill
Other companies: Telix Pharmaceuticals Limited (Chair & Independent Non-Executive Director · Since Apr 2, 2026); Y mAbs Therapeutics (Director · Since at least Sep 20, 2018); Evolus, Inc. Common Stock (Director · Since at least Feb 12, 2018); Strongbridge Biopharma plc (Director · Sep 3, 2019 – Oct 5, 2021 · Past); STRATA Skin Sciences, Inc. (Director · May 30, 2018 – Nov 22, 2019 · Past); Melinta Therapeutics Inc (Director · May 25, 2018 – Jun 11, 2019 · Past); Cempra Inc (Director · Jan 1, 2016 – Jan 3, 2017 · Past); EndoChoice Holdings Inc (President and CFO · Aug 14, 2015 – Nov 22, 2016 · Past)
Director · Dec 9, 2016 – Jun 15, 2018 · Past
Kevin Rakin
Other companies: Elutia, Inc. (Chairman · Since at least Oct 7, 2020); Quantum-Si Incorporated (Director · Since at least Sep 3, 2020); Oramed Pharmaceuticals Inc. (Director · Aug 30, 2016 – Mar 21, 2022 · Past)
Director · Dec 2, 2014 – Feb 8, 2019 · Past
Marna C Whittington
Other companies: Phillips 66 (Director · Since at least May 9, 2012); Brookfield Oaktree Holdings, LLC (Director · Jun 28, 2012 – Sep 30, 2019 · Past); Macy's Inc (Director · Sep 30, 2011 – May 21, 2021 · Past)
Director · Mar 21, 2022 – Jun 28, 2024 · Past
Lynne E Kelley
Other companies: X4 Pharmaceuticals, Inc. (See Remarks · Apr 24, 2019 – Apr 24, 2019 · Past); Senseonics Holdings, Inc. (Chief Medical Officer · Mar 17, 2016 – Feb 2, 2018 · Past)
Chief Medical Officer · Jul 31, 2018 – Oct 1, 2018 · Past
Prabhavathi Fernandes
Other companies: CapForce Inc. (Director · Apr 1, 2020 – Jun 7, 2023 · Past); Cempra Inc (President and CEO, Director · Feb 2, 2012 – Jan 1, 2016 · Past)
Director · Apr 5, 2020 – Nov 26, 2024 · Past
Quan Vu
Other companies: Monopar Therapeutics Inc. (Chief Financial Officer, Principal Accounting Officer, and Principal Financial Officer · Since at least Mar 3, 2025); Forum Markets, Incorporated (COO / Chief Business Officer · Oct 29, 2021 – Dec 16, 2021 · Past)
CFO/CBO · Mar 6, 2023 – Mar 6, 2023 · Past
Sanjay Subramanian
Other companies: Scynexis, Inc. (Chief Financial Officer · Since at least Sep 9, 2026); Inozyme Pharma Inc (SVP, CFO & Head of BD · Since at least Mar 21, 2022)
Chief Financial Officer · Oct 1, 2019 – Jan 3, 2022 · Past
Satishchandran Chandrasekhar
Other companies: Statera Biopharma, Inc. (Director · Feb 22, 2022 – Feb 22, 2022 · Past); Marizyme, Inc. (Chief Operating Officer · Jul 31, 2020 – Jul 31, 2020 · Past)
Director · Since at least Jun 5, 2025
Blaise Coleman
Other companies: Endo International PLC (President, CEO, Director · Nov 22, 2016 – Mar 29, 2022 · Past)
Director · Since at least Jun 5, 2025
All 44 people
PersonSeat
David C. Hood
Other companies: Fathom Holdings Inc. (Director · Since at least Jul 28, 2020)
Director · Jul 19, 2019 – Jul 19, 2019 · Past
Frank Leo
Other companies: Rxelite Inc (Director · Feb 13, 2008 – Jun 4, 2008 · Past)
Director · Sep 27, 2019 – Jan 2, 2020 · Past
Kirsten Castillo
Other companies: ACV Auctions Inc. (Director · Since at least Mar 23, 2021)
Director · Since at least Apr 5, 2020
Abhi GuptaExecutive Vice President, Commercial and Business Development · Since at least Sep 30, 2026
Arun UpadhyayChief Scientific Officer, Head of Research & Development · Since at least Jan 1, 2023
Chris ClarkVP Communications · Since at least Oct 22, 2026
Daniel JorgensenChief Medical Officer · Sep 27, 2019 – May 5, 2020 · Past
Donald HautChief Business Officer · Jun 5, 2017 – Oct 1, 2018 · Past
Gloria MatthewsChief Medical Officer · Jul 14, 2015 – Feb 14, 2017 · Past
Huma QamarChief Medical Officer · Mar 18, 2024 – Jan 2, 2025 · Past
Jessica CrespoCAO/SVP, Finance · Jan 3, 2023 – Jan 3, 2023 · Past
John ZhangDirector · Since at least Nov 5, 2026
Jolanda CrombachGeneral Manager of the Company’s European affiliate · Oct 6, 2026 – Nov 5, 2026 · Past
Junge ZhangDirector · Since at least Sep 27, 2019
Kevin McArdleChief Financial Officer · Dec 2, 2014 – Feb 26, 2015 · Past
Manish PottiDirector · Sep 27, 2019 – Dec 16, 2021 · Past
Michael BreiningerSee Remarks · Sep 15, 2023 – Sep 15, 2023 · Past
Michael LewisDirector · Dec 2, 2014 – Feb 8, 2019 · Past
Mohamed GeneadChief Medical Officer · Since at least Sep 1, 2026
Nancy LynchChief Medical Officer · Dec 2, 2014 – Dec 2, 2014 · Past
Paul StaidExecutive Vice President, Operations · Since at least Nov 4, 2026
Ramesh KumarDirector · Sep 27, 2019 – Jun 9, 2023 · Past
Ramesh RamachandranChief Accounting Officer · Since at least Nov 14, 2024
Rasappa ArumughamChief Scientific Officer · Sep 27, 2019 – May 5, 2020 · Past
Rita Johnson-GreeneChief Financial Officer · Since at least Feb 9, 2026
Satish ChandranDirector · Since at least Nov 5, 2026
Shankar MusunuriChairman of the Board, CEO and Co-founder · Since at least Sep 27, 2019
Stephen Richard KennedyChief Operating Officer · Feb 14, 2017 – Oct 1, 2018 · Past
Suha TaspolatogluDirector · Jan 1, 2021 – Jan 1, 2021 · Past
Susan B WasherDirector · Apr 16, 2018 – Apr 16, 2018 · Past
Tiffany HamiltonAVP, Head of Communications · Since at least Apr 29, 2026
Treerita Essalima Johnson-GreeneChief Financial Officer · Since at least Mar 4, 2026
Uday B. KompellaCo-founder and Director · Since at least Sep 27, 2019
Vijay TammaraChief Development Officer · Since at least Sep 27, 2019

Open People

Log in to ask 6ix AI your own questions about Ocugen, Inc.